Storia in 2 fonti

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

Raccontata da

morningstar.com

healio.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

morningstar.comStai leggendo1 mese fa

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric…

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

originale

healio.com1 mese fa

FDA approves Skyrizi for pediatric use in psoriatic disease

The FDA approved risankizumab-rzaa for children aged at least 6 years with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy or active psoriatic arthritis, AbbVie announced in a…

Leggi questa versione →

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

Confronto fonti

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric…

FDA approves Skyrizi for pediatric use in psoriatic disease

Timeline cronologica

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe…

Pediatric Dermatology News

FDA approves Skyrizi for pediatric use in psoriatic disease